Abstract. Histone deacetylase 5 (HDAC5), as a member of the class IIa family of HDACs, is frequently dysregulated in human malignancies. However, little is known regarding the specific role of HDAC5 in lung cancer. We aimed to evaluate HDAC5 expression in human lung cancer and to determine the effects of HDAC5 on lung cancer cells. First, the expression levels of both HDAC5 protein and mRNA were evaluated in lung cancer tissues and cell lines by western blot analysis and RT-qPCR, and the results suggested that HDAC5 was significantly upregulated in human lung cancer tissues and cell lines. To address the effects of HDAC5 on the biological behavior of human lung adenocarcinoma cells, we generated human lung cancer A549 cell lines in which HDAC5 was either overexpressed or depleted. The results indicated that overexpression of HDAC5 significantly promoted the proliferation and invasion, and inhibited the apoptosis of A549 cells. On the contrary, HDAC5 knockdown largely decreased the proliferation and invasion and enhanced the apoptosis of A549 cells. Furthermore, we demonstrated that HDAC5 overexpression promoted the expression of DLL4, Six1, Notch 1 and Twist 1 in A549 cells. Downregulation of HDAC5 caused a significant inhibition of the expression of DLL4, Six1, Notch 1 and Twist 1 in A549 cells. Taken together, our data demonstrated that HDAC5 displayed a significant upregulation in lung cancer, and elevated HDAC5 might be involved in the potentiation of proliferation and invasion of lung cancer cells, as well as the inhibition of lung cancer cell apoptosis by the upregulation of DLL4, Six1, Notch 1 and Twist 1. The present study may provide an evidence for the potential application of HDAC5 inhibitors in the therapy of lung cancer.

Introduction

Lung cancer is a debilitating neoplasm, and accounts for significant morbidity and mortality worldwide (1). Despite significant progress seen in the last decade in regards to treatment regimens including surgery, radiotherapy and chemotherapy, and ongoing research development, the survival rate of patients with lung cancer is still less than satisfactory. A substantial number of patients succumb to the disease within the weeks following diagnosis, and the 5-year survival rate does not exceed 15% (2-5). The poor prognosis of lung cancer mainly results from its high degree of malignancy (malignant proliferation, invasion and migration). Most patients with lung cancer do not die of primary cancer, but rather die of metastatic cancer (6,7). Therefore, the key molecules that mediate lung cancer metastasis have become a focus of scientific research.

The histone deacetylases (HDACs) form a family of enzymes, which have fundamental roles in the epigenetic regulation of gene expression and contribute to proliferation, differentiation, apoptosis and cell cycle progression (8-10). HDACs are frequently dysregulated in human malignancies and have therefore become therapeutic targets in cancer therapy (11). As a member of the class IIa family of HDACs, histone deacetylase 5 (HDAC5) is known to undergo nuclear-cytoplasmic shuttling and to be a prominent regulator of cellular and epigenetic processes that underlie the progression of human disease, including cardiac diseases and tumorigenesis (12-14). A growing body of literature suggests that HDAC5 is extensively expressed in many cancers. Li et al demonstrated that HDAC5 was extensively expressed in human breast cancer tissues, and high HDAC5 expression was associated with poor patient prognosis. Downregulation of HDAC5 was found to suppress breast cancer cell proliferation, invasion and migration, and promote breast cancer cell apoptosis (15). He et al showed that HDAC5 was upregulated in human colorectal cancer. Overexpression of HDAC5 significantly improved the proliferation of colorectal cancer cells. On the contrary, HDAC5 knockdown was found to suppress colorectal tumor cell growth (8). Feng et al showed that
HDAC5 was increased in human hepatocellular carcinoma. Overexpression of HDAC5 promoted liver cancer cell proliferation, and inhibition of HDAC5 significantly inhibited liver cancer cell proliferation (16). Chen et al. found that HDAC5 was upregulated in osteosarcoma, and overexpression of HDAC5 promoted the proliferation of osteosarcoma cells. In contrast, HDAC5 knockdown inhibited the proliferation of osteosarcoma cells (9). Liu et al. demonstrated that HDAC5 displayed high expression in melanoma cells compared with normal skin cells. HDAC5 knockdown was found to suppress the proliferation and metastasis of melanoma cells (17). Milde et al. found that HDAC5 displayed a significant upregulation in high-risk medulloblastoma compared with low-risk medulloblastoma, and the upregulation of HDAC5 was associated with poor patient survival (18). In summary, HDAC5 has been found to play an important role in tumorigenesis, metastasis and invasion (16-18). However, little is known regarding the specific role of HDAC5 in lung cancer.

In the present study, lung cancer cell lines (A549, HCC827 and 95-D) and human bronchial epithelial cells (HBE) were used to detect the expression of HDAC5 by western blotting and RT-qPCR. The effects of HDAC5 on A549 cell proliferation, apoptosis and invasion were assayed. In addition, we analyzed the effects of HDAC5 on the expression of proteins, DLL4 (Delta-like 4), Six1, Notch 1 and Twist 1 in A549 cells. These data may provide information for the prediction of lung cancer prognosis and the establishment of targeted therapies.

Materials and methods

Specimens. The present study was reviewed and approved by the Ethics Committee of the Affiliated Hospital of Nantong University. All patients volunteered to participate in the study and signed a written informed consent. Fresh lung cancer tissues and matched adjacent non-tumor tissues were collected from 18 non-small cell lung cancer (NSCLC) patients that underwent surgical resection at the Affiliated Hospital of Nantong University from July 2015 to January 2017. The median patient age was 61 years (range, 48-72 years) and 13 patients (72.2%) were male. Before surgery, all the patients received no radiotherapy and chemotherapy, and had no other treatment history, nor presented with inflammatory diseases. All tissue specimens collected from patients with NSCLC were immediately frozen in liquid nitrogen upon surgery, and were transported to the laboratory and stored at -80°C for further tissue preparation.

Materials. All cell culture reagents were obtained from Gibco/Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Human lung cancer cell lines (A549, HCC827 and 95-D) and human bronchial epithelial (HBE) cells (https://www.atcc.org/Products/All/PCS-300-010.aspx) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Protein extraction buffer, MTT reagent, BCA protein concentration assay kit, Annexin V-FITC and propidium iodide (PI) were purchased from Beyotime Institute of Biotechnology (Haimen, China). Polyvinylidene difluoride (PVDF) membranes were supplied by Millipore (Bedford, MA, USA). Pierce ECL chemiluminescence detection kit was obtained from Thermo Fisher Scientific, Inc. Transwell invasion chamber was supplied by Costar Corp. (Cambridge, MA, USA). Matrigel was purchased from Collaborative Biomedical Products (Bedford, MA, USA). The antibodies used in this study included rabbit anti-HDAC5 polyclonal antibody (Abcam, Cambridge, UK; cat. no. ab55403), rabbit anti-delta-like 4 (DLL4) antibody (Cell Signaling Technology, Inc., Danvers, MA, USA; cat. no. 2589T), rabbit anti-SIX homeobox 1 (SIX1) antibody (LifeSpan Biosciences, Seattle, WA, USA; cat. no. LS-C490560-100), mouse anti-Notch 1 monoclonal antibody (Invitrogen Antibodies/Thermo Fisher Scientific, Inc.; cat. no. MA1-81888), rabbit anti-Twist 1 polyclonal antibody (Cell Signaling Technology, Inc.; cat. no. 46702S), mouse anti-β-actin monoclonal antibody (R&D Systems, Minneapolis, MN, USA; cat. no. MAB8929), horseradish peroxidase-conjugated goat anti-rabbit (cat. no. 31239) and goat anti-mouse (cat. no. 31185) IgG polyclonal antibodies (Invitrogen Antibodies/Thermo Fisher Scientific, Inc.).

Cell culture and treatment. HBE cells and A549, HCC827 and 95-D cells were all cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 50 U/ml penicillin and 50 μg/ml streptomycin at 37°C in a humidified atmosphere with 5% CO2. When cells reached 70-80% confluence, trypsin digestion was performed for passage. Cells in logarithmic growth phase were digested with 0.25% trypsin and collected for further experiments. A549 cells were chosen to perform further experiments. A549 cells (2x10⁵) were seeded in a 6-well tissue culture plate with 2 ml antibiotic-free RPMI-1640 medium supplemented with 10% FBS. When cells reached 60-80% confluence, the cells were transfected with HDAC5 siRNA, pcDNA3.1-HDAC5 and control vector (Guangzhou RiboBio Co., Ltd., Guangzhou, China) using Invitrogen™ Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer's specification. Then, A549 cells were incubated with the compound at 37°C in a CO2 incubator for 5 h. Following, the transfection mixture was replaced with fresh medium to culture for 48 h. Finally, the A549 cells were assayed using the appropriate protocol.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RT-qPCR was selected to determine the expression of HDAC5 mRNA. The primers for HDAC5 (GenBank: BC051824.1) were: Left primer gttgagcaggtg-gttgaagg and right primer agtccacgatgaggaccttg. The primers for β-actin (GenBank: M10277.1) were: Left primer cttc-ttcagcctcctctcct and right primer agcaacctgtggagctcac. Total RNA was extracted using Trizol reagent obtained from Beyotime Institute of Biotechnology (cat. no. R0016). Then mRNAs were reverse transcribed into cDNA using BeyoRT™ cDNA Synthesis Kit (Beyotime Institute of Biotechnology; cat. no. D7166), qPCR analyses were performed using the BeyoFast™ SYBR Green qPCR Mix (Beyotime Institute of Biotechnology; cat. no. D7260) on Applied Biosystems 7500 Real-Time PCR Systems (Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for qPCR. Firstly 95°C for 5 min, followed by 36 cycles of 95°C for 10 sec, 60°C for 30 sec, and 72°C 30 sec. The genes β-actin was used as internal control for RT-qPCR. All RT-PCRs were performed in triplicate and the mean value was used for all experiments.
performed in triplicate and the relative fold differences in gene expression were calculated according to the $2^{ΔΔCt}$ method.

**Western blot analysis.** Total proteins were extracted from lung cancer tissues, lung cancer-adjacent normal tissues, lung cancer cell lines (A549, HCC827 and 95-D) and HBE cells using a protein extraction kit, and were quantified using a BCA protein concentration assay kit. Proteins were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane using a wet-type transblotting apparatus (Bio-Rad Laboratories, Richmond, CA, USA). Then the PVDF membrane was blocked with 5% skimmed milk diluted in TBS (10 mM Tris-HCl, pH 7.5, 150 mM NaCl) solution for 1 h, and incubated with the primary antibody at 4˚C overnight. All primary antibodies were diluted 1:2,000 in TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.1% Tween-20) supplemented with 5% non-fat milk. Next morning, the PVDF membrane was washed 3x5 min in TBST and bands were visualized using the ECL chemiluminescence reagent. The relative expression of the target protein was evaluated with the gray value ratio of target protein content to β-actin (target protein/β-actin content) by Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).

**MTT assay.** MTT assay was used to examine the effects of HDAC5 on the viability of A549 cells. Briefly, A549 cells were seeded in 96-well plates and allowed to adhere overnight. Then, A549 cells were incubated with 10 µl of MTT (5 mg/ml) for 4 h. The mixture culture medium was replaced by 150 µl of dimethyl sulfoxide (DMSO) to dissolve the crystals. The optical density (OD) values at 570 nm (test wavelength) and 630 nm (reference wavelength) were examined on a 96-well micro test spectrophotometer (BioTek Instruments, Inc., Winooski, VT, USA). The relative cell viability was calculated by the equation as described in a previous study (19) and the experiments were run in triplicate.

**Flow cytometric analysis.** The effects of HDAC5 on the A549 cell cycle and apoptosis were determined using flow cytometry. First, A549 cells were seeded in serum-free RPMI-1640 medium for 24 h to synchronize and then incubated with complete RPMI-1640 medium for 24 h. Following, A549 cells were trypsinized, washed, harvested, fixed with 70% ice-cold
ethanol and stored at -20°C. On the next day, A549 cells were washed with citrate phosphate buffer and PBS in turn, treated with PBS containing 100 µg/ml of RNase A at 37°C for 30 min, and then cultured in PBS containing 100 µg/ml of propidium iodide (PI) at room temperature for 30 min. Finally, cell cycle distribution was determined using flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). The experiments were performed in triplicate.

A549 cell apoptosis was quantitated by staining with Annexin V-FITC. Briefly, A549 cells were washed, collected, and resuspended in 195 µl of Annexin V-FITC binding buffer. Following, 5 µl of Annexin V-FITC was added into the Annexin V-FITC binding buffer and incubated in the dark at room temperature for 10 min. Then, A549 cells were collected by centrifugation for 5 min at 1,500 x g, and gently resuspended in 190 µl of Annexin V-FITC binding buffer. Finally, 10 µl of PI staining solution was added into the Annexin V-FITC binding buffer and kept on ice in the dark until flow cytometric analysis. CellQuest software (BD Biosciences) was used to analyze the datum, and the analysis was run in triplicate.

Transwell invasion analysis. Transwell invasion chamber was used to evaluate the invasive ability of the A549 cells. Briefly, the chamber filter was washed with serum-free RPMI-1640 medium, and then the upper side of the filter was evenly covered with 20 µl of Matrigel (1:2 dilution with RPMI-1640). The chamber was divided by two compartments including the upper chamber and the lower chamber. For invasion assays, 200 µl of serum-free RPMI-1640 medium containing 1x10^5 A549 cells were added in the upper chamber of the Transwell invasion system, while 500 µl of RPMI-1640 medium containing 10% FBS were added into the lower chamber. Then the Transwell invasion system was incubated for 48 h in an incubator. Following, the cells on the upper surface of the filter were removed with a sterile cotton swab. Those cells that invaded to the lower surface of the filter and invaded in the lower chamber were collected and assessed by MTT assay. The results are presented as the mean ± SD, and the experiment was performed in triplicate.

Statistical analysis. All data are expressed as mean ± SD from at least three independent experiments. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used to analyze the experimental data with Student's t-test or one-way ANOVA followed by Tukey's post hoc test. The results were considered statistically significant at P<0.05. GraphPad Prism software version 5.0 (GraphPad Software, Inc., San Diego, CA, USA) was applied to draw the graphs.

Results

Overexpression of HDAC5 in lung cancer tissues and cell lines. We first examined HDAC5 protein and mRNA levels in human lung cancer tissues by western blotting and RT-qPCR. The results showed that the expression of HDAC5 protein and mRNA was significantly upregulated in lung cancer tissues compared to that observed in the lung cancer-adjacent normal tissues (P<0.05) (Fig. 1A and B). The expression profile of HDAC5 protein and mRNA in lung cancer tissues were similar to those in lung cancer cell lines, which showed that HDAC5 protein and mRNA displayed significant upregulation in human lung cancer cell lines (A549, HCC827 and 95-D) compared to that observed in the human bronchial epithelial (HBE) cells (P<0.05) (Fig. 1C and D). These data demonstrated that the elevated HDAC5 may be important in the tumorigenesis and progression of lung cancer.

In order to address the function of HDAC5 in the tumorigenesis and progression of lung cancer, A549 cells were chosen for further investigation unless specified otherwise. We generated A549 cells in which HDAC5 was either overexpressed or depleted. Western blot analysis indicated that the expression of HDAC5 protein was significantly
upregulated in the HDAC5 overexpression group (transfected with pcDNA3.1-HDAC5) (P<0.05), and was obviously downregulated in the HDAC5-knockdown group (transfected with HDAC5 siRNA) compared to the control group (NC, transfected with vector only) (P<0.05) (Fig. 2), which suggested that A549 cell models, in which HDAC5 was either overexpressed or depleted, were successfully established.

**HDAC5 enhances A549 cell viability.** In order to explore the effect of HDAC5 on the cell viability of lung cancer cells, MTT assay was performed and the results suggested that A549 cell viability was significantly enhanced in the HDAC5 overexpression group compared with the control group (P<0.05), while the cell viability of A549 cells was markedly inhibited in the HDAC5 knockdown group compared with the control group (P<0.05) (Fig. 3). These data indicated that elevated HDAC5 may play a crucial role in the increase in A549 cell viability.

**HDAC5 promotes A549 cell cycle progression.** In order to address whether HDAC5 is associated with A549 cell cycle progression, we evaluated the cell cycle distribution of A549 cells by FCM. The results indicated that there were more A549 cells in the S and G2 phases, and less A549 cells in the G1 phase in the HDAC5 overexpression group compared to these populations in the control group (P<0.05). On the contrary, there were less A549 cells in the S and G2 phases, and more A549 cells in the G1 phase in the HDAC5 knockdown group compared to these populations in the control group (P<0.05) (Fig. 4). These data demonstrated that HDAC5 may promote A549 cell cycle progression.
ZHONG et al: HISTONE DEACETYLASE 5 IN LUNG CANCER CELLS

HDAC5 inhibits A549 cell apoptosis. In order to ascertain whether HDAC5 is associated with A549 cell apoptosis, we evaluated the cell apoptosis of A549 cells by FCM. The results showed that there were less apoptotic A549 cells in the HDAC5 overexpression group than that in the control group (P<0.05). On the contrary, more apoptotic A549 cells were found in the HDAC5 knockdown group compared to that in the control group (P<0.05) (Fig. 5). These data suggested that HDAC5 plays a crucial role in the inhibition of A549 cell apoptosis.

HDAC5 enhances the invasive ability of A549 cells. To determine whether HDAC5 is associated with A549 cell invasion, Transwell invasion assay was used to evaluate the effect of HDAC5 on A549 cells. The results suggested that the OD value of the invaded A549 cells in the HDAC5 overexpression group was higher than that in the control group (P<0.05). On the contrary, a lower OD value was found in the HDAC5 knockdown group compared to that in the control group (P<0.05) (Fig. 6). These data demonstrated that more A549 cells invaded through the polycarbonate membrane in HDAC5 overexpression group, and less A549 cells invaded through the polycarbonate membrane in HDAC5 knockdown group compared to control group, which indicated that HDAC5 strengthen the invasive ability of A549 cells.

Discussion

Lung cancer is one of the most common malignant neoplasms, as well as the most common cause of cancer-related mortality. Most lung cancers are squamous cell carcinomas, small cell carcinomas or adenocarcinomas (21). The prognosis of patients with lung cancer is still less than satisfactory, and the 5-year survival rate does not exceed 15% (2-5). This is mainly due to the fact that many key factors regulating the malignant phenotype of lung cancer have not been studied clearly. HDAC5 is frequently dysregulated in human malignancies and has therefore become a therapeutic target in cancer therapy (8,9,11,16,20). However, whether HDAC5 is involved in lung cancer incidence, migration and invasion remains elusive.

In the present study, our data showed that HDAC5 displayed significantly high expression in lung cancer tissues and cell lines. The expression profile of HDAC5 in lung cancer was consistent with that in breast cancer, colorectal cancer and glioma (8,15,22). Elevated HDAC5 was found to promote the proliferation of colorectal cancer cells through upregulation of DLL4 (8). HDAC5 was found to be increased in human glioma tissues and to promote the proliferation of glioma cells by the...
upregulation of Notch 1 (20). These data indicate that elevated HDAC5 may play a central role in the tumorigenesis of lung cancer.

In order to elucidate the role of HDAC5 in lung cancer cells, A549 cell models, in which HDAC5 was either overexpressed or depleted, were generated. HDAC5 displayed a higher expression in the HDAC5 overexpression group and a lower expression in the HDAC5 knockdown group compared to the control group, which indicated that the A549 cell models were successfully established. In view of the established lung cancer A549 cell models, the effects of HDAC5 on cell viability, cell cycle distribution, apoptosis and invasion of A549 cells were determined, and the results showed that HDAC5 overexpression enhanced the cell viability and proliferation of A549 cells. On the contrary, HDAC5 inhibition suppressed the cell viability and proliferation of A549 cells, leading to cell growth inhibition and cell cycle G1 phase arrest in A549 cells. These data indicated that HDAC5 improved the cell growth and proliferation of A549 cells. The effect on the proliferation of A549 cells was consistent with that of other cancers reported by previous studies which demonstrated that elevated HDAC5 promoted the proliferation of colorectal cancer cells, hepatocellular carcinoma cells and glioma cells, while downregulation of HDAC5 caused a significant inhibition of colorectal cancer cell, hepatocellular carcinoma cell and glioma cell proliferation (8,16,20). The results also showed that overexpression of HDAC5 displayed an obvious inhibition of A549 cell apoptosis, and the inhibition of HDAC5 facilitated A549 cell apoptosis, which indicated that HDAC5 inhibited A549 cell apoptosis. The results in this study were also confirmed by previous studies concerning breast cancer and hepatocellular carcinoma, which reported that knockdown of HDAC5 reduced tumorigenesis and enhanced apoptosis (15,22-24). HDAC5 was extensively expressed in many human cancers. HDAC5, overexpressed in neuroblastoma, was found to trigger neuroblastoma cell invasion and metastasis (25), and knockdown of HDAC5 restrained breast cancer cell proliferation, invasion and metastasis (15). Furthermore, the effect of HDAC5 on A549 cell invasion was evaluated by Transwell invasion assay. The results revealed that overexpression of HDAC5 was associated with the increased invasive capacity of A549 cells, and the inhibition of HDAC5 was associated with the decreased invasive capacity of A549 cells.

In summary, these results demonstrated that HDAC5 was associated with increased A549 cell growth, proliferation, and invasion and decreased A549 cell apoptosis. Nevertheless, the detailed mechanism or the downstream HDAC5 targets in human lung cancer cells remains unclear. HDAC5 promoted colorectal cancer cell proliferation by upregulating DLL4 expression (8), glioma cell proliferation by upregulation of Notch 1 (20), human hepatocellular carcinoma cell proliferation by upregulating Six1 expression (16), and osteosarcoma progression by upregulation of Twist 1 expression (9). Therefore, the expression levels of DLL4, Six1, Notch 1 and Twist 1 were also determined in this study, and the results indicated that HDAC5 increased the expression of DLL4, Six1, Notch 1 and Twist 1 in the A549 cells. Our results were in line with the results from previous studies that found that overexpression of DLL4 was associated with poor outcomes of patients with pancreatic adenocarcinoma, and elevated DLL4 promoted renal carcinoma cell metastasis (26,27). Thus, we may speculate that elevated HDAC5 promotes the expression of DLL4 in lung cancer, and contributes to poor patient outcomes and metastasis. Increased Six1 was found to be associated with the poor prognosis of prostate cancer patients and enhanced pancreatic cancer cell proliferation through upregulation of cyclin D1 (28,29). Conversely, downregulation of Six1 suppressed colorectal cancer cell growth and invasion (30). From our results, we could infer that elevated HDAC5 could promote the expression of Six1 in lung cancer, and contribute to lung cancer cell proliferation and poor prognosis. Notch 1 signaling, activated in many cancers, promoted the malignant features including epithelial to mesenchymal transition of cancers through NF-κB activation (31,32). Notably, DLL4-Notch signaling was found to participate in the formation of large vessels in tumors, leading to distant metastasis of tumors (33). Inhibition of Notch 1 signaling pathway was found to inhibit breast cancer cell
proliferation and invasion (34). Twist 1, a key factor in the promotion of metastasis of cancer cells, promoted cell growth and metastasis in acute myeloid leukemia (35,36). In view of these data, we may conjecture that elevated HDAC5 in lung cancer could promote the expression of Notch 1 and Twist 1, and then promote EMT and distant metastasis. HDAC5 could repress the expression of miR-125a-5p in human breast cancer (22). Our previous study showed that miR-125a-5p was downregulated and acted as a tumor suppressor in lung carcinoma by directly targeting STAT3 (37). These data may be responsible for the explanation that HDAC5 promoted A549 cell growth, proliferation, invasion and inhibited A549 cell apoptosis.

In summary, our data demonstrated that HDAC5 was significantly upregulated in lung cancer, and elevated HDAC5 may be involved in the potentiation of proliferation and invasion of lung cancer cells, as well as the inhibition of lung cancer cell apoptosis, at least partially, by the upregulation of DLL4, Six1, Notch 1 and Twist 1 (Fig. 8). This study provides evidence for the potential application of HDAC5 inhibitors in the therapy of lung cancer.

Acknowledgements

We thank Dr Hualin Sun for his technical support.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81501967).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

LZ and JHS conceived and designed the study. LZ, SYS, SMY, MMG and XH performed the experiments. LZ wrote the paper. LZ and JHS conceived and designed the study. LZ, SYS, SMY, MMM, XH and JHS reviewed and edited the manuscript. MMG and XH performed the experiments. LZ wrote the paper. LZ and JHS conceived and designed the study. LZ, SYS, SMY, MMM, XH and JHS reviewed and edited the manuscript. MMG and XH performed the experiments. LZ wrote the paper.

Ethics approval and consent to participate

The present study was reviewed and approved by the Ethics Committee of the Affiliated Hospital of Nantong University. All patients volunteered to participate in the study and signed a written informed consent. The authors declare that they have no competing interests.

References


